AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Stock Performance

ABBV opened at $142.55 on Wednesday. The firm has a market cap of $252.04 billion, a P/E ratio of 20.19, a price-to-earnings-growth ratio of 3.99 and a beta of 0.70. AbbVie has a 52-week low of $105.56 and a 52-week high of $175.91. The company has a debt-to-equity ratio of 4.15, a quick ratio of 0.75 and a current ratio of 0.84. The business's fifty day moving average is $146.68 and its 200-day moving average is $150.53.

AbbVie (NYSE:ABBV - Get Rating) last released its earnings results on Friday, July 29th. The company reported $3.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.42 by $0.09. The company had revenue of $14.58 billion for the quarter, compared to analyst estimates of $14.64 billion. AbbVie had a return on equity of 158.41% and a net margin of 22.03%. AbbVie's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm posted $3.11 EPS. Sell-side analysts expect that AbbVie will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 15th. Investors of record on Friday, July 15th were given a dividend of $1.41 per share. The ex-dividend date of this dividend was Thursday, July 14th. This represents a $5.64 annualized dividend and a dividend yield of 3.96%. AbbVie's dividend payout ratio is currently 79.89%.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent analyst reports. Morgan Stanley decreased their target price on AbbVie from $191.00 to $188.00 and set an "overweight" rating on the stock in a report on Monday, August 1st. Wells Fargo & Company boosted their target price on AbbVie from $165.00 to $200.00 in a report on Monday, May 2nd. Atlantic Securities decreased their target price on AbbVie from $178.00 to $162.00 and set a "neutral" rating on the stock in a report on Monday, August 1st. BMO Capital Markets boosted their target price on AbbVie from $161.00 to $174.00 and gave the stock an "outperform" rating in a report on Monday, April 25th. Finally, Daiwa Capital Markets lowered AbbVie from an "outperform" rating to a "neutral" rating and set a $150.00 target price on the stock. in a report on Friday, May 6th. One analyst has rated the stock with a sell rating, six have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $159.63.

Insider Buying and Selling

In related news, Vice Chairman Michael Severino sold 79,801 shares of the company's stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $150.90, for a total transaction of $12,041,970.90. Following the completion of the sale, the insider now directly owns 152,103 shares in the company, valued at approximately $22,952,342.70. The sale was disclosed in a filing with the SEC, which is available through this link. 0.08% of the stock is owned by corporate insiders.